Catalyst Event
Sanofi (SNY) · Other
From KEDI Global Longevity Bio Index (KGLB)
3/18/2026, 12:00:00 AM
Sanofi's Phase 3 clinical trial (COAST 2) for amlitelimab in atopic dermatitis was updated as completed on March 18, 2026, signaling that top-line data results are expected to be released soon.
Korean Translation
사노피의 아토피 피부염 치료제 암리텔리맙에 대한 3상 임상시험(COAST 2)이 2026년 3월 18일 완료된 것으로 업데이트되어, 주요 데이터 결과 발표가 임박했음을 시사함.
Related Recent Events
Biogen Inc (BIIB) · Other
U.S. FDA decision (PDUFA date) for LEQEMBI IQLIK (lecanemab) subcutaneous autoinjector for treatment initiation in Alzheimer's disease on 2026-05-24; high importance is estimated as FDA approval for a major drug formulation typically results in ≥10% price impact, scheduled.
5/24/2026, 12:00:00 AM
Exelixis Inc (EXEL) · Earnings Release
Exelixis is expected to report its Q1 2026 earnings on or around May 12, 2026, and analysts forecast EPS of approximately $0.73-$0.76; high importance reflects potential volatility from earnings surprises, forecasted and scheduled.
5/12/2026, 12:00:00 AM
Eli Lilly and Co (LLY) · Earnings Release
Q1 2026 earnings release scheduled. Analysts forecast EPS around $7.25-$7.50 estimated. High importance estimated due to the significant weight of earnings reports on stock volatility.
4/30/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Earnings Release
Bristol Myers Squibb Q1 2026 results conference call is scheduled for 2026-04-30; as the next earnings catalyst following the strong Q4 2025 outlook, a multi-percent share move is reasonably expected based on typical earnings volatility scheduled.
4/30/2026, 12:00:00 AM
Teva Pharmaceutical Industries Ltd (TEVA) · Earnings Release
Teva is scheduled to release its financial results for the first quarter of 2026 before the market opens on April 29, 2026, followed by a conference call with management; a 5% price impact is estimated for this earnings release, scheduled.
4/29/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
First quarter 2026 earnings release; importance is estimated as Medium because quarterly earnings reports often result in price movements exceeding 5%, scheduled.
4/24/2026, 12:00:00 AM